Global Castrate-Resistant Prostate Cancer Market By Therapy (Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy), By Region, Industry Analysis and Forecast, 2020 - 2026
Published Date : 3-Feb-2021 |
Pages: 124 |
Formats: PDF |
COVID-19 Impact on the Castrate-Resistant Prostate Cancer Market
Market Overview
The Global Castrate-resistant Prostate Cancer Market size is expected to reach $14.5 billion by 2026, rising at a market growth of 8.3% CAGR during the forecast period. Castrate-Resistant Prostate Cancer (CRPC), a variety of prostate cancer that generally recurs after managing androgen deprivation therapy (ADC), is getting prominent in the prostate cancer market.
The global market of CRPC is estimated to rise at a notable rate, due to high unmet clinical requirements, increasing prevalence rates, limited survival benefits, and fast-emerging treatment modifications. The market growth will depend on the unique breakthrough treatments responsible for securing survival benefits. The survival benefit is helpful in controlling the peak sales and market penetration of novel approved drugs.
Shifting treatment patterns, arising untapped non-metastatic CRPC space, promising drug pipeline, and increased patient awareness are the factors that are estimated to propel the market growth. Moreover, the untapped CRPC market in the Asia-Pacific and LAMEA region will also boost the overall market growth over the forecast period. Untapped non-metastatic CRPC settings will further accelerate the market growth. However, factors like uncertain reimbursement policies, premium pricing of CRPC drugs, and lack of distinction in the mechanism of action between the approved and novel agents are expected to restrain the market growth.
The increasing prevalence of castrate-resistant prostate cancer, rising adoption of novel drugs, coupled with an unhealthy lifestyle are the main factors predicted to boost the market growth. The requirement for fast treatment alternatives and funding in R&D by leading companies will also contribute to the growth of the market.
By Therapy
Based on Therapy, the market is segmented into Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy. The hormonal therapy category garnered the highest revenue share in the castrate-resistant prostate cancer market in 2019. This growth is due to the presence of a huge number of approved drugs, the introduction of new drugs, and the growth of the product portfolio. Additionally, the growing advancement of innovative medicines to fulfill unmet requirements and current treatment options is estimated to propel the growth of the market for castrate-resistant prostate cancer.
By Region
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America recorded the highest revenue share in the castrate-resistant prostate cancer market in 2019 and is estimated to sustain the figures during the forecast period. This growth is due to the high prevalence of the disease, the existence of regional players, and supportive reimbursement policies. Changing lifestyle is another factor that adds to the prevalence of diseases.
| Report Attribute | Details |
|---|---|
| Market size value in 2019 | USD 8.4 Billion |
| Market size forecast in 2026 | USD 14.5 Billion |
| Base Year | 2019 |
| Historical Period | 2016 to 2018 |
| Forecast Period | 2020 to 2026 |
| Revenue Growth Rate | CAGR of 8.3% from 2020 to 2026 |
| Number of Pages | 124 |
| Number of Tables | 180 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
| Segments covered | Therapy, Region |
| Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
| Growth Drivers |
|
| Restraints |
|
Free Valuable Insights: Global Castrate-Resistant Prostate Cancer Market to reach a market size of $14.5 billion by 2026
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.).
Recent Strategies Deployed in Castrate-Resistant Prostate Cancer Market
- Dec-2019: Pfizer Inc. and Astellas Pharma Inc. announced that FDA approved their supplemental New Drug Application (sNDA) for XTANDI (enzalutamide). This has been used for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
- Oct-2019: The Janssen Pharmaceutical Companies of Johnson & Johnson announced that it received the approval from FDA for its Breakthrough Therapy Designation for niraparib, an orally-administered poly ADP-ribose polymerase (PARP) inhibitor. This inhibitor is used for the treatment of patients with BRCA1/2 gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
- Jul-2019: Bayer AG got FDA approval for Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi) product. This product is used for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
- Mar-2019: Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi) product of Bayer AG got approval from European Commission. This product is used for the treatment of men with non-metastatic castration-resistant prostate cancer.
- Jun-2018: Astellas Pharma launched 40 mg XTANDI (generic name enzalutamide) Tablets and 80 mg XTANDI Tablets in Japan for the treatment of castration-resistant prostate cancer.
- Feb-2018: The Janssen Pharmaceutical Companies of Johnson & Johnson announced that FDA approved its ERLEADA (apalutamide), a next-generation androgen receptor inhibitor. The inhibitor is used for the treatment of patients with non-metastatic castration-resistant prostate cancer (NM-CRPC).
- Dec-2016: Sanofi Genzyme, business unit of Sanofi announced agreement with Scottish Medicines Consortium (SMC). Following this agreement, Jevtana (cabazitaxel), a product of Sanofi is being used in NHS Scotland for the treatment of metastatic hormone-refractory prostate cancer (mHRPC) by Scottish Medicines Consortium (SMC).
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Hormonal Therapy
- Immunotherapy
- Chemotherapy
- Radiotherapy
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Sanofi S.A.
- Johnson and Johnson
- Pfizer, Inc.
- Bayer AG
- Abbott Laboratories
- GlaxoSmithKline PLC (GSK)
- Northwest Biotherapeutics, Inc.
- Active Biotech AB
- Astellas Pharma, Inc.
- Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Table of contents
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Castrate-Resistant Prostate Cancer Market, by Therapy
1.4.2 Global Castrate-Resistant Prostate Cancer Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market
Chapter 4. Global Castrate-resistant Prostate Cancer Market by Therapy
4.1 Global Hormonal Therapy Market by Region
4.2 Global Immunotherapy Market by Region
4.3 Global Chemotherapy Market by Region
4.4 Global Radiotherapy Market by Region
Chapter 5. Global Castrate-resistant Prostate Cancer Market by Region
5.1 North America Castrate-resistant Prostate Cancer Market
5.1.1 North America Castrate-resistant Prostate Cancer Market by Therapy
5.1.1.1 North America Hormonal Therapy Market by Country
5.1.1.2 North America Immunotherapy Market by Country
5.1.1.3 North America Chemotherapy Market by Country
5.1.1.4 North America Radiotherapy Market by Country
5.1.2 North America Castrate-resistant Prostate Cancer Market by Country
5.1.2.1 US Castrate-resistant Prostate Cancer Market
5.1.2.1.1 US Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.2 Canada Castrate-resistant Prostate Cancer Market
5.1.2.2.1 Canada Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.3 Mexico Castrate-resistant Prostate Cancer Market
5.1.2.3.1 Mexico Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.4 Rest of North America Castrate-resistant Prostate Cancer Market
5.1.2.4.1 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy
5.2 Europe Castrate-resistant Prostate Cancer Market
5.2.1 Europe Castrate-resistant Prostate Cancer Market by Therapy
5.2.1.1 Europe Hormonal Therapy Market by Country
5.2.1.2 Europe Immunotherapy Market by Country
5.2.1.3 Europe Chemotherapy Market by Country
5.2.1.4 Europe Radiotherapy Market by Country
5.2.2 Europe Castrate-resistant Prostate Cancer Market by Country
5.2.2.1 Germany Castrate-resistant Prostate Cancer Market
5.2.2.1.1 Germany Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.2 UK Castrate-resistant Prostate Cancer Market
5.2.2.2.1 UK Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.3 France Castrate-resistant Prostate Cancer Market
5.2.2.3.1 France Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.4 Russia Castrate-resistant Prostate Cancer Market
5.2.2.4.1 Russia Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.5 Spain Castrate-resistant Prostate Cancer Market
5.2.2.5.1 Spain Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.6 Italy Castrate-resistant Prostate Cancer Market
5.2.2.6.1 Italy Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.7 Rest of Europe Castrate-resistant Prostate Cancer Market
5.2.2.7.1 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy
5.3 Asia Pacific Castrate-resistant Prostate Cancer Market
5.3.1 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
5.3.1.1 Asia Pacific Hormonal Therapy Market by Country
5.3.1.2 Asia Pacific Immunotherapy Market by Country
5.3.1.3 Asia Pacific Chemotherapy Market by Country
5.3.1.4 Asia Pacific Radiotherapy Market by Country
5.3.2 Asia Pacific Castrate-resistant Prostate Cancer Market by Country
5.3.2.1 China Castrate-resistant Prostate Cancer Market
5.3.2.1.1 China Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.2 Japan Castrate-resistant Prostate Cancer Market
5.3.2.2.1 Japan Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.3 India Castrate-resistant Prostate Cancer Market
5.3.2.3.1 India Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.4 South Korea Castrate-resistant Prostate Cancer Market
5.3.2.4.1 South Korea Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.5 Singapore Castrate-resistant Prostate Cancer Market
5.3.2.5.1 Singapore Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.6 Malaysia Castrate-resistant Prostate Cancer Market
5.3.2.6.1 Malaysia Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.7 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market
5.3.2.7.1 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
5.4 LAMEA Castrate-resistant Prostate Cancer Market
5.4.1 LAMEA Castrate-resistant Prostate Cancer Market by Therapy
5.4.1.1 LAMEA Hormonal Therapy Market by Country
5.4.1.2 LAMEA Immunotherapy Market by Country
5.4.1.3 LAMEA Chemotherapy Market by Country
5.4.1.4 LAMEA Radiotherapy Market by Country
5.4.2 LAMEA Castrate-resistant Prostate Cancer Market by Country
5.4.2.1 Brazil Castrate-resistant Prostate Cancer Market
5.4.2.1.1 Brazil Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.2 Argentina Castrate-resistant Prostate Cancer Market
5.4.2.2.1 Argentina Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.3 UAE Castrate-resistant Prostate Cancer Market
5.4.2.3.1 UAE Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.4 Saudi Arabia Castrate-resistant Prostate Cancer Market
5.4.2.4.1 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.5 South Africa Castrate-resistant Prostate Cancer Market
5.4.2.5.1 South Africa Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.6 Nigeria Castrate-resistant Prostate Cancer Market
5.4.2.6.1 Nigeria Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.7 Rest of LAMEA Castrate-resistant Prostate Cancer Market
5.4.2.7.1 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Johnson and Johnson
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental &Regional Analysis
6.2.4 Research & Development Expenses
6.2.1 Recent strategies and developments:
6.2.1.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.4 Bayer AG
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Approvals:
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Northwest Biotherapeutics, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expense
6.8 Active Biotech AB
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.9 Astellas Pharma, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product Launches and Product Expansions:
6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
6.10.1 Company Overview
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Castrate-Resistant Prostate Cancer Market, by Therapy
1.4.2 Global Castrate-Resistant Prostate Cancer Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Recent Developments in Global Castrate-resistant Prostate Cancer Market
Chapter 4. Global Castrate-resistant Prostate Cancer Market by Therapy
4.1 Global Hormonal Therapy Market by Region
4.2 Global Immunotherapy Market by Region
4.3 Global Chemotherapy Market by Region
4.4 Global Radiotherapy Market by Region
Chapter 5. Global Castrate-resistant Prostate Cancer Market by Region
5.1 North America Castrate-resistant Prostate Cancer Market
5.1.1 North America Castrate-resistant Prostate Cancer Market by Therapy
5.1.1.1 North America Hormonal Therapy Market by Country
5.1.1.2 North America Immunotherapy Market by Country
5.1.1.3 North America Chemotherapy Market by Country
5.1.1.4 North America Radiotherapy Market by Country
5.1.2 North America Castrate-resistant Prostate Cancer Market by Country
5.1.2.1 US Castrate-resistant Prostate Cancer Market
5.1.2.1.1 US Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.2 Canada Castrate-resistant Prostate Cancer Market
5.1.2.2.1 Canada Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.3 Mexico Castrate-resistant Prostate Cancer Market
5.1.2.3.1 Mexico Castrate-resistant Prostate Cancer Market by Therapy
5.1.2.4 Rest of North America Castrate-resistant Prostate Cancer Market
5.1.2.4.1 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy
5.2 Europe Castrate-resistant Prostate Cancer Market
5.2.1 Europe Castrate-resistant Prostate Cancer Market by Therapy
5.2.1.1 Europe Hormonal Therapy Market by Country
5.2.1.2 Europe Immunotherapy Market by Country
5.2.1.3 Europe Chemotherapy Market by Country
5.2.1.4 Europe Radiotherapy Market by Country
5.2.2 Europe Castrate-resistant Prostate Cancer Market by Country
5.2.2.1 Germany Castrate-resistant Prostate Cancer Market
5.2.2.1.1 Germany Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.2 UK Castrate-resistant Prostate Cancer Market
5.2.2.2.1 UK Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.3 France Castrate-resistant Prostate Cancer Market
5.2.2.3.1 France Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.4 Russia Castrate-resistant Prostate Cancer Market
5.2.2.4.1 Russia Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.5 Spain Castrate-resistant Prostate Cancer Market
5.2.2.5.1 Spain Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.6 Italy Castrate-resistant Prostate Cancer Market
5.2.2.6.1 Italy Castrate-resistant Prostate Cancer Market by Therapy
5.2.2.7 Rest of Europe Castrate-resistant Prostate Cancer Market
5.2.2.7.1 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy
5.3 Asia Pacific Castrate-resistant Prostate Cancer Market
5.3.1 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
5.3.1.1 Asia Pacific Hormonal Therapy Market by Country
5.3.1.2 Asia Pacific Immunotherapy Market by Country
5.3.1.3 Asia Pacific Chemotherapy Market by Country
5.3.1.4 Asia Pacific Radiotherapy Market by Country
5.3.2 Asia Pacific Castrate-resistant Prostate Cancer Market by Country
5.3.2.1 China Castrate-resistant Prostate Cancer Market
5.3.2.1.1 China Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.2 Japan Castrate-resistant Prostate Cancer Market
5.3.2.2.1 Japan Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.3 India Castrate-resistant Prostate Cancer Market
5.3.2.3.1 India Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.4 South Korea Castrate-resistant Prostate Cancer Market
5.3.2.4.1 South Korea Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.5 Singapore Castrate-resistant Prostate Cancer Market
5.3.2.5.1 Singapore Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.6 Malaysia Castrate-resistant Prostate Cancer Market
5.3.2.6.1 Malaysia Castrate-resistant Prostate Cancer Market by Therapy
5.3.2.7 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market
5.3.2.7.1 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy
5.4 LAMEA Castrate-resistant Prostate Cancer Market
5.4.1 LAMEA Castrate-resistant Prostate Cancer Market by Therapy
5.4.1.1 LAMEA Hormonal Therapy Market by Country
5.4.1.2 LAMEA Immunotherapy Market by Country
5.4.1.3 LAMEA Chemotherapy Market by Country
5.4.1.4 LAMEA Radiotherapy Market by Country
5.4.2 LAMEA Castrate-resistant Prostate Cancer Market by Country
5.4.2.1 Brazil Castrate-resistant Prostate Cancer Market
5.4.2.1.1 Brazil Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.2 Argentina Castrate-resistant Prostate Cancer Market
5.4.2.2.1 Argentina Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.3 UAE Castrate-resistant Prostate Cancer Market
5.4.2.3.1 UAE Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.4 Saudi Arabia Castrate-resistant Prostate Cancer Market
5.4.2.4.1 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.5 South Africa Castrate-resistant Prostate Cancer Market
5.4.2.5.1 South Africa Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.6 Nigeria Castrate-resistant Prostate Cancer Market
5.4.2.6.1 Nigeria Castrate-resistant Prostate Cancer Market by Therapy
5.4.2.7 Rest of LAMEA Castrate-resistant Prostate Cancer Market
5.4.2.7.1 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy
Chapter 6. Company Profiles
6.1 Sanofi S.A.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.2 Johnson and Johnson
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental &Regional Analysis
6.2.4 Research & Development Expenses
6.2.1 Recent strategies and developments:
6.2.1.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.4 Bayer AG
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Approvals:
6.5 Abbott Laboratories
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Northwest Biotherapeutics, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expense
6.8 Active Biotech AB
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Research & Development Expense
6.9 Astellas Pharma, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.9.5 Recent strategies and developments:
6.9.5.1 Product Launches and Product Expansions:
6.10. Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
6.10.1 Company Overview
List of Tables
TABLE 1 Global Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 2 Global Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 3 Global Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 4 Global Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 5 Global Hormonal Therapy Market by Region, 2016 - 2019, USD Million
TABLE 6 Global Hormonal Therapy Market by Region, 2020 - 2026, USD Million
TABLE 7 Global Immunotherapy Market by Region, 2016 - 2019, USD Million
TABLE 8 Global Immunotherapy Market by Region, 2020 - 2026, USD Million
TABLE 9 Global Chemotherapy Market by Region, 2016 - 2019, USD Million
TABLE 10 Global Chemotherapy Market by Region, 2020 - 2026, USD Million
TABLE 11 Global Radiotherapy Market by Region, 2016 - 2019, USD Million
TABLE 12 Global Radiotherapy Market by Region, 2020 - 2026, USD Million
TABLE 13 Global Castrate-resistant Prostate Cancer Market by Region, 2016 - 2019, USD Million
TABLE 14 Global Castrate-resistant Prostate Cancer Market by Region, 2020 - 2026, USD Million
TABLE 15 North America Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 16 North America Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 17 North America Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 18 North America Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 19 North America Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 20 North America Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 21 North America Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 22 North America Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 23 North America Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 24 North America Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 25 North America Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 26 North America Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 27 North America Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 28 North America Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 29 US Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 30 US Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 31 US Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 32 US Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 33 Canada Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 34 Canada Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 35 Canada Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 36 Canada Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 37 Mexico Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 38 Mexico Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 39 Mexico Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 40 Mexico Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 41 Rest of North America Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 42 Rest of North America Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 43 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 44 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 45 Europe Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 46 Europe Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 47 Europe Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 48 Europe Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 49 Europe Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 50 Europe Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 51 Europe Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 52 Europe Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 53 Europe Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 54 Europe Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 55 Europe Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 56 Europe Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 57 Europe Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 58 Europe Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 59 Germany Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 60 Germany Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 61 Germany Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 62 Germany Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 63 UK Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 64 UK Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 65 UK Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 66 UK Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 67 France Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 68 France Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 69 France Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 70 France Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 71 Russia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 72 Russia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 73 Russia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 74 Russia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 75 Spain Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 76 Spain Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 77 Spain Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 78 Spain Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 79 Italy Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 80 Italy Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 81 Italy Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 82 Italy Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 83 Rest of Europe Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 84 Rest of Europe Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 85 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 86 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 87 Asia Pacific Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 88 Asia Pacific Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 89 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 90 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 91 Asia Pacific Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 92 Asia Pacific Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 93 Asia Pacific Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 94 Asia Pacific Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 95 Asia Pacific Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 96 Asia Pacific Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 97 Asia Pacific Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 98 Asia Pacific Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 99 Asia Pacific Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 100 Asia Pacific Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 101 China Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 102 China Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 103 China Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 104 China Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 105 Japan Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 106 Japan Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 107 Japan Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 108 Japan Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 109 India Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 110 India Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 111 India Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 112 India Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 113 South Korea Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 114 South Korea Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 115 South Korea Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 116 South Korea Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 117 Singapore Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 118 Singapore Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 119 Singapore Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 120 Singapore Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 121 Malaysia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 122 Malaysia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 123 Malaysia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 124 Malaysia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 125 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 126 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 127 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 128 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 129 LAMEA Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 130 LAMEA Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 131 LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 132 LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 133 LAMEA Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 134 LAMEA Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 135 LAMEA Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 136 LAMEA Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 137 LAMEA Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 138 LAMEA Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 139 LAMEA Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 140 LAMEA Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 141 LAMEA Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 142 LAMEA Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 143 Brazil Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 144 Brazil Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 145 Brazil Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 146 Brazil Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 147 Argentina Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 148 Argentina Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 149 Argentina Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 150 Argentina Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 151 UAE Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 152 UAE Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 153 UAE Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 154 UAE Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 155 Saudi Arabia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 156 Saudi Arabia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 157 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 158 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 159 South Africa Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 160 South Africa Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 161 South Africa Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 162 South Africa Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 163 Nigeria Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 164 Nigeria Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 165 Nigeria Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 166 Nigeria Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 167 Rest of LAMEA Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 168 Rest of LAMEA Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 169 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 170 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 171 Key Information – Sanofi S.A.
TABLE 172 Key information –Johnson and Johnson
TABLE 173 Key Information – Pfizer, Inc.
TABLE 174 Key Information – Bayer AG
TABLE 175 Key Information – Abbott Laboratories
TABLE 176 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 177 Key Information – Northwest Biotherapeutics, Inc.
TABLE 178 Key Information – Active Biotech AB
TABLE 179 key information – Astellas Pharma, Inc.
TABLE 180 Key Information – Dendreon Pharmaceuticals LLC
List of Figures
FIG 1 Methodology for the research
TABLE 2 Global Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 3 Global Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 4 Global Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 5 Global Hormonal Therapy Market by Region, 2016 - 2019, USD Million
TABLE 6 Global Hormonal Therapy Market by Region, 2020 - 2026, USD Million
TABLE 7 Global Immunotherapy Market by Region, 2016 - 2019, USD Million
TABLE 8 Global Immunotherapy Market by Region, 2020 - 2026, USD Million
TABLE 9 Global Chemotherapy Market by Region, 2016 - 2019, USD Million
TABLE 10 Global Chemotherapy Market by Region, 2020 - 2026, USD Million
TABLE 11 Global Radiotherapy Market by Region, 2016 - 2019, USD Million
TABLE 12 Global Radiotherapy Market by Region, 2020 - 2026, USD Million
TABLE 13 Global Castrate-resistant Prostate Cancer Market by Region, 2016 - 2019, USD Million
TABLE 14 Global Castrate-resistant Prostate Cancer Market by Region, 2020 - 2026, USD Million
TABLE 15 North America Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 16 North America Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 17 North America Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 18 North America Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 19 North America Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 20 North America Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 21 North America Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 22 North America Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 23 North America Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 24 North America Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 25 North America Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 26 North America Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 27 North America Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 28 North America Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 29 US Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 30 US Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 31 US Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 32 US Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 33 Canada Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 34 Canada Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 35 Canada Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 36 Canada Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 37 Mexico Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 38 Mexico Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 39 Mexico Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 40 Mexico Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 41 Rest of North America Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 42 Rest of North America Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 43 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 44 Rest of North America Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 45 Europe Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 46 Europe Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 47 Europe Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 48 Europe Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 49 Europe Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 50 Europe Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 51 Europe Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 52 Europe Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 53 Europe Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 54 Europe Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 55 Europe Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 56 Europe Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 57 Europe Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 58 Europe Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 59 Germany Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 60 Germany Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 61 Germany Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 62 Germany Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 63 UK Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 64 UK Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 65 UK Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 66 UK Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 67 France Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 68 France Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 69 France Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 70 France Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 71 Russia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 72 Russia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 73 Russia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 74 Russia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 75 Spain Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 76 Spain Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 77 Spain Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 78 Spain Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 79 Italy Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 80 Italy Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 81 Italy Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 82 Italy Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 83 Rest of Europe Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 84 Rest of Europe Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 85 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 86 Rest of Europe Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 87 Asia Pacific Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 88 Asia Pacific Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 89 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 90 Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 91 Asia Pacific Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 92 Asia Pacific Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 93 Asia Pacific Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 94 Asia Pacific Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 95 Asia Pacific Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 96 Asia Pacific Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 97 Asia Pacific Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 98 Asia Pacific Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 99 Asia Pacific Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 100 Asia Pacific Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 101 China Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 102 China Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 103 China Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 104 China Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 105 Japan Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 106 Japan Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 107 Japan Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 108 Japan Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 109 India Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 110 India Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 111 India Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 112 India Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 113 South Korea Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 114 South Korea Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 115 South Korea Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 116 South Korea Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 117 Singapore Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 118 Singapore Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 119 Singapore Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 120 Singapore Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 121 Malaysia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 122 Malaysia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 123 Malaysia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 124 Malaysia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 125 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 126 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 127 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 128 Rest of Asia Pacific Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 129 LAMEA Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 130 LAMEA Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 131 LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 132 LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 133 LAMEA Hormonal Therapy Market by Country, 2016 - 2019, USD Million
TABLE 134 LAMEA Hormonal Therapy Market by Country, 2020 - 2026, USD Million
TABLE 135 LAMEA Immunotherapy Market by Country, 2016 - 2019, USD Million
TABLE 136 LAMEA Immunotherapy Market by Country, 2020 - 2026, USD Million
TABLE 137 LAMEA Chemotherapy Market by Country, 2016 - 2019, USD Million
TABLE 138 LAMEA Chemotherapy Market by Country, 2020 - 2026, USD Million
TABLE 139 LAMEA Radiotherapy Market by Country, 2016 - 2019, USD Million
TABLE 140 LAMEA Radiotherapy Market by Country, 2020 - 2026, USD Million
TABLE 141 LAMEA Castrate-resistant Prostate Cancer Market by Country, 2016 - 2019, USD Million
TABLE 142 LAMEA Castrate-resistant Prostate Cancer Market by Country, 2020 - 2026, USD Million
TABLE 143 Brazil Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 144 Brazil Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 145 Brazil Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 146 Brazil Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 147 Argentina Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 148 Argentina Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 149 Argentina Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 150 Argentina Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 151 UAE Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 152 UAE Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 153 UAE Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 154 UAE Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 155 Saudi Arabia Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 156 Saudi Arabia Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 157 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 158 Saudi Arabia Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 159 South Africa Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 160 South Africa Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 161 South Africa Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 162 South Africa Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 163 Nigeria Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 164 Nigeria Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 165 Nigeria Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 166 Nigeria Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 167 Rest of LAMEA Castrate-resistant Prostate Cancer Market, 2016 - 2019, USD Million
TABLE 168 Rest of LAMEA Castrate-resistant Prostate Cancer Market, 2020 - 2026, USD Million
TABLE 169 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2016 - 2019, USD Million
TABLE 170 Rest of LAMEA Castrate-resistant Prostate Cancer Market by Therapy, 2020 - 2026, USD Million
TABLE 171 Key Information – Sanofi S.A.
TABLE 172 Key information –Johnson and Johnson
TABLE 173 Key Information – Pfizer, Inc.
TABLE 174 Key Information – Bayer AG
TABLE 175 Key Information – Abbott Laboratories
TABLE 176 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 177 Key Information – Northwest Biotherapeutics, Inc.
TABLE 178 Key Information – Active Biotech AB
TABLE 179 key information – Astellas Pharma, Inc.
TABLE 180 Key Information – Dendreon Pharmaceuticals LLC
List of Figures
FIG 1 Methodology for the research